BioArctic announces Novartis' decision to terminate their collaboration agreement, affecting ongoing research efforts in neurodegenerative diseases.

BioArctic AB has revealed the members of its Nomination Committee for the 2027 Annual General Meeting, emphasizing shareholder representation.

BioArctic AB has unveiled the members of its Nomination Committee ahead of the 2027 Annual General Meeting, reflecting significant shareholder representation.

At the upcoming CTAD conference, Eisai and BioArctic will share groundbreaking data regarding lecanemab's effectiveness in Alzheimer's treatment spanning five years.

BioArctic (BIOA B) received notice that Novartis Pharma has decided to terminate their agreement exploring a potential combination treatment. The Option, Collaboration and License Agreement, entered into in August 2025, paired BioArctic's BrainTransporter technology with an undisclosed Novartis antibody. BioArctic said the termination follows Novartis's decision to discontinue the program and is unrelated to BrainTransporter.BioArctic will retain the full USD 30 million upfront payment and recognize its remaining unrecognized portion as revenue in 2026. The company has entered into five collaboration agreements using BrainTransporter to date.

BioArctic has announced that Novartis Pharma AG has decided to terminate their collaboration agreement signed in August 2025, affecting a planned treatment exploring innovative technology.

BioArctic's partner Eisai reports that Leqembi® generated 32.2 billion yen in sales during the third quarter of 2026, marking a significant royalty increase for BioArctic.

Eisai is set to share groundbreaking findings about lecanemab's long-term effectiveness and real-world application at the CTAD conference 2026, showcasing data from various studies.

In Q3 2026, Leqembi® sales hit 32.2 billion yen, marking a substantial growth. BioArctic's royalties increased significantly, showcasing the drug's success.

BioArctic (BIOA B) has appointed its Nomination Committee to prepare proposals for the company's 2027 Annual General Meeting.The committee comprises Margareta Öhrvall, appointed by Demban; Pär Gellerfors, appointed by Ackelsta; and chair Thomas Ehlin, representing Fjärde AP-fonden. The Board Chair serves as convener. The represented shareholders held approximately 57 percent of shares and 82 percent of votes as of September 30, 2026. The annual meeting will take place in Stockholm on May 27, 2027, at 4.30 pm CEST. Committee proposals will appear in the meeting notice and on the company's website.

The first patient in Sweden has begun treatment with Leqembi, a groundbreaking Alzheimer's therapy, marking a significant development in available healthcare options for early-stage patients.

The recent debut of Leqembi at a Swedish clinic signifies a historic moment in Alzheimer's treatment, providing hope to early-stage patients.

Japan has approved the Leqembi® Pen, offering a new subcutaneous treatment option for early Alzheimer's disease, enhancing patient autonomy.

The Canadian Drug Agency has recommended Leqembi® for public reimbursement, marking a significant step in treating Alzheimer's disease in Canada.

The Canadian Drug Agency has positively recommended public reimbursement for Leqembi, effective for early Alzheimer's disease patients, marking a significant healthcare milestone.